Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Adult
Antibodies, Monoclonal, Humanized
Bexarotene
Cost-Benefit Analysis
Humans
Mycosis Fungoides
/ drug therapy
Quality-Adjusted Life Years
Randomized Controlled Trials as Topic
Sezary Syndrome
/ drug therapy
Skin Neoplasms
/ drug therapy
State Medicine
Technology
Technology Assessment, Biomedical
Vorinostat
Journal
PharmacoEconomics
ISSN: 1179-2027
Titre abrégé: Pharmacoeconomics
Pays: New Zealand
ID NLM: 9212404
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
accepted:
26
09
2021
pubmed:
20
10
2021
medline:
18
5
2022
entrez:
19
10
2021
Statut:
ppublish
Résumé
The National Institute for Health and Care Excellence (NICE) invited the manufacturer (Kyowa Kirin) of mogamulizumab (Poteligeo
Identifiants
pubmed: 34664200
doi: 10.1007/s40273-021-01098-3
pii: 10.1007/s40273-021-01098-3
pmc: PMC9095533
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Vorinostat
58IFB293JI
Bexarotene
A61RXM4375
mogamulizumab
YI437801BE
Types de publication
Journal Article
Review
Systematic Review
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
509-518Subventions
Organisme : Department of Health
Pays : United Kingdom
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021. The Author(s).
Références
Lancet Oncol. 2018 Sep;19(9):1192-1204
pubmed: 30100375
Value Health. 2012 Jul-Aug;15(5):708-15
pubmed: 22867780
Value Health. 2020 Mar;23(3):388-396
pubmed: 32197735
Lancet. 2017 Aug 5;390(10094):555-566
pubmed: 28600132
Stat Methods Med Res. 2017 Apr;26(2):724-751
pubmed: 25416688
J Clin Oncol. 2016 Oct 1;34(28):3426-33
pubmed: 27507878